国际医药卫生导报2013，Vol.19Issue(16)：2527-2530,4.DOI:10.3760/cma.j.issn.1007-1245.2013.16.030
培美曲塞和卡铂对比紫杉醇和卡铂同期放化疗治疗局部晚期非小细胞肺癌的临床研究
Clinical comparison study on pemetrexed combined with carboplatin versus paclitaxel combined with carboplatin as concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
王智辉 1吴庭安 1陈春花 1彭雨 1黄秀芳 1林大任1
作者信息
摘要
Abstract
Objective To observe the effect and clinical toxicity of pemetrexed combined with carboplatin versus paclitaxel combined with carboplatin with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC).Methods Total of 60 patients stage Ⅲ NSCLC (ⅢA 39 patients,ⅢB 21 patients) were randomly assigned into two groups.Pemetrexed combined with carboplatin group:accepted pemetrexed 500 mg/m2,d1,carboplatin AUC 5,d1,once every 21 days.Paclitaxel combined with carboplatin group:paclitaxel 150 mg/m2,d1,carboplatin AUC 5,d1,once every 21 days.Two groups both accepted 3-D conformal radiation therapy (3D-CRT) during chemotherapy.The total dose was 60 ～ 70 Gy.After radiation therapy,the patients were accepted 2 ～ 3 cycles of chemotherapy.Results The efficacy of pemetrexed combined with carboplatin and paclitaxel combined with carboplatin were 44.83％ and 29.03％ respectively.The disease control rates of two groups were 79.31％ and 67.74％ respectively.The differences were statistically significant (P＜0.05).The adverse reactions of pemetrexed group were rare.Two groups of median progression-free survival were 12.5 and 9.9 months respectively.1 year overall survival was 58.62％ and 48.39％ respectively.The differences were also significant (P＜0.05).Conclusion Pemetrexed combined with carboplatin can be used as stage Ⅲ NSCLC patients treated with concurrent chemoradiation regimens during optimization.Toxicity was tolerable.Pemetrexed group was better than paclitaxel group in disease control rates and survival.关键词
培美曲塞/紫杉醇/同期放化疗/非小细胞肺癌Key words
Pemetrexed/ Paclitaxel/ Concurrent chemoradiotherapy/ Non-small cell lung cancer引用本文复制引用
王智辉,吴庭安,陈春花,彭雨,黄秀芳,林大任..培美曲塞和卡铂对比紫杉醇和卡铂同期放化疗治疗局部晚期非小细胞肺癌的临床研究[J].国际医药卫生导报,2013,19(16):2527-2530,4.
